Trial Profile
A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Finerenone (Primary) ; Eplerenone
- Indications Chronic heart failure; Left ventricular dysfunction
- Focus Pharmacodynamics
- Acronyms ARTS-HF
- Sponsors Bayer
- 29 Apr 2016 Results (n=1066) published in the European Heart Journal
- 14 Apr 2016 Results of ARTS-HF study in Japanese patients (n=72) published in the Circulation Journal.
- 31 Aug 2015 Results published in a Bayer Media Release.